Journal of Tuberculosis and Lung Disease ›› 2022, Vol. 3 ›› Issue (6): 517-520.doi: 10.19983/j.issn.2096-8493.20220148
• Review Articles • Previous Articles Next Articles
Chen Qiuqi1, Wu Chaoling2, Zhang Peize3, Deng Guofang3()
Received:
2022-09-14
Online:
2022-12-20
Published:
2022-12-15
Contact:
Deng Guofang
E-mail:jxxk1035@yeah.net
Supported by:
CLC Number:
Chen Qiuqi, Wu Chaoling, Zhang Peize, Deng Guofang. Current status and prospect of screening and treatment of latent multidrug-resistant tuberculosis infection[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(6): 517-520. doi: 10.19983/j.issn.2096-8493.20220148
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.jtbld.cn/EN/10.19983/j.issn.2096-8493.20220148
[1] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
[2] |
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0.
doi: 10.1016/S0140-6736(21)02724-0 URL pmid: 35065702 |
[3] |
Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond), 2017, 49(3):161-169. doi:10.1080/23744235.2016.1262059.
doi: 10.1080/23744235.2016.1262059 URL |
[4] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018. |
[5] |
Knight GM, McQuaid CF, Dodd PJ, et al. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis, 2019, 19(8): 903-912. doi:10.1016/S1473-3099(19)30307-X.
doi: S1473-3099(19)30307-X URL pmid: 31281059 |
[6] |
Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med, 2015, 3(12):963-972. doi:10.1016/S2213-2600(15)00458-0.
doi: 10.1016/S2213-2600(15)00458-0 URL pmid: 26597127 |
[7] |
Shah NS, Yuen CM, Heo M, et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis, 2014, 58 (3): 381-391. doi:10.1093/cid/cit643.
doi: 10.1093/cid/cit643 URL pmid: 24065336 |
[8] |
Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis, 2016, 16(10):1193-1201. doi:10.1016/S1473-3099(16)30132-3.
doi: S1473-3099(16)30132-3 URL pmid: 27342768 |
[9] |
Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014, 383(9928):1572-1579. doi:10.1016/S0140-6736(14)60195-1.
doi: 10.1016/S0140-6736(14)60195-1 URL pmid: 24671080 |
[10] |
Mehra M, Cossrow N, Kambili C, et al. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int J Tuberc Lung Dis, 2013, 17(9):1186-1194. doi:10.5588/ijtld.12.0959.
doi: 10.5588/ijtld.12.0959 URL pmid: 23827732 |
[11] | Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Latent tuberculosis infection: a guide for primary health care providers-Diagnosis of latent TB infection. Atlanta: Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 2020. |
[12] | World Health Organization. WHO operational handbook on tuberculosis (Module 1-Prevention): tuberculosis preventive treatment. Geneva: World Health Organization, 2020. |
[13] |
Li R, Nordio F, Huang CC, et al. Two Clinical Prediction Tools to Improve Tuberculosis Contact Investigation. Clin Infect Dis, 2020, 71(8): e338-e350. doi:10.1093/cid/ciz1221.
doi: 10.1093/cid/ciz1221 URL pmid: 31905406 |
[14] |
Saunders MJ, Wingfield T, Tovar MA, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis, 2017, 17(11):1190-1199. doi:10.1016/S1473-3099(17)30447-4.
doi: S1473-3099(17)30447-4 URL pmid: 28827142 |
[15] | World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015. |
[16] |
Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis, 2017, 64(12):1670-1677. doi:10.1093/cid/cix208.
doi: 10.1093/cid/cix208 URL pmid: 28329197 |
[17] |
Gupta A, Swindells S, Kim S, et al. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis, 2020, 70(3):425-435. doi:10.1093/cid/ciz235.
doi: 10.1093/cid/ciz235 URL pmid: 30942853 |
[18] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management background document on the 2019 revision. Geneva: World Health Organization, 2019. |
[19] |
Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009—2012. Int J Tuberc Lung Dis, 2014, 18(8): 912-918. doi:10.5588/ijtld.13.0028.
doi: 10.5588/ijtld.13.0028 URL |
[20] | World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015. |
[21] |
Holland DP, Sanders GD, Hamilton CD, et al. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One, 2012, 7(1): e30194. doi:10.1371/journal.pone.0030194.
doi: 10.1371/journal.pone.0030194 URL |
[22] |
Fox GJ, Oxlade O, Menzies D. Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. Am J Respir Crit Care Med, 2015, 192(2):229-237. doi:10.1164/rccm.201501-0069OC.
doi: 10.1164/rccm.201501-0069OC URL |
[23] |
Schluger NW. Prevention of Multidrug-Resistant Tuberculosis in Close Contacts. Back to the Future? Am J Respir Crit Care Med, 2020, 202(8):1077-1078. doi:10.1164/rccm.202006-2488ED.
doi: 10.1164/rccm.202006-2488ED URL |
[24] |
Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB mana-gement of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis, 2020, 92S:S15-S25. doi:10.1016/j.ijid.2020.01.042.
doi: 10.1016/j.ijid.2020.01.042 URL |
[25] |
Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019, 200(10): e93-e142. doi:10.1164/rccm.201909-1874ST.
doi: 10.1164/rccm.201909-1874ST URL |
[26] |
Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med, 2018, 6(9):662-664. doi:10.1016/S2213-2600(18)30329-1.
doi: 10.1016/S2213-2600(18)30329-1 URL pmid: 30191832 |
[27] |
Gureva T, Turkova A, Yablokova E, et al. Fluoroquinolone preventive therapy for children exposed to MDR-TB. Int J Tuberc Lung Dis, 2022, 26(2):171-173. doi:10.5588/ijtld.21.0443.
doi: 10.5588/ijtld.21.0443 URL pmid: 35086631 |
[28] |
Huang CC, Becerra MC, Calderon R, et al. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med, 2020, 202(8): 1159-1168. doi:10.1164/rccm.201908-1576OC.
doi: 10.1164/rccm.201908-1576OC URL |
[29] |
Moore DA. What can we offer to 3 million MDRTB household contacts in 2016?. BMC Med, 2016, 14: 64. doi:10.1186/s12916-016-0610-x.
doi: 10.1186/s12916-016-0610-x URL |
[30] | 中华人民共和国国家卫生健康委员会办公厅. 结核病预防控制工作技术规范(2020年版). 2020-04-02. |
[1] | Huang Wei, Shen Yinzhong. Key issues of diagnosis and treatment of acquired immunodeficiency syndrome complicated with tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(6): 431-436. |
[2] | Li Yan, Han Tongxin, Piao Yurong, Mao Huawei. Clinical analysis of five children with joint tuberculosis misdiagnosed juvenile idiopathic arthritis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(5): 364-370. |
[3] | Lin Huimin, Fu Yu, Fang Zhangfu, Xie Jiaxing. Research progress on eosinophilic asthma [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 328-333. |
[4] | He Yanchao, Jie Zhijun. Strategy of early screening for active pulmonary tuberculosis in general hospital [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 334-337. |
[5] | LIU Hui-min, TIAN Yao, BEI Cheng-li, FU Man-jiao. Application and prospect of immunological detection technology for active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(1): 70-74. |
[6] | WU Di, FAN Xin-xin, SHEN Jian-shan, LIN You-fei, CHEN Xiao-hong, HUANG Ming-xiang, CHEN Li-zhou. Diagnostic value of combined detection of coagulation screening indicators and D-dimer in clinical classification of COVID-19 [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(4): 355-360. |
[7] | ZOU Xia-li, YANG Hai-mei, ZENG Ran-yuan, WU Zi-jian, TANG Qiong, LI Jue, CHEN Qian-you. Investigation and analysis of tuberculosis epidemic situation in a school in Wugang, Hu’nan [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(4): 366-369. |
[8] | ZHANG Qun-cheng, LI Xiang-nan, XU Zhi-wei, SUN Guan-nan, YANG Hui-zhen, CHENG Dong-jun, ZHANG Xiao-ju. Diagnostic value of bronchoscopic cryobiopsy for diagnosing peripheral lung nodule [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 205-209. |
[9] | CUI Kai, ZHANG Xiao-ju. Research progress on the application of biomarkers in differential diagnosis of benign and malignant pulmonary nodules [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 273-276. |
[10] | LI Jing, ZHANG Yan, WU Qian-hong. Research progress on free DNA detection of Mycobacterium tuberculosis of non-sputum samples in tuberculosis diagnosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 277-282. |
[11] | JIANG You-li, ZHANG Pei-ze, DENG Guo -fang, CHEN Jing-fang. Research progress of delay in diagnosis of tuberculosis and its influencing factors [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 289-293. |
[12] | LIU Sheng-sheng, TANG Shen-jie. Interpretation of the Guidelines for diagnosis and treatment of non-tuberculous mycobacteria disease (2020 edition) [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 108-115. |
[13] | LUO Xue-jiao, SHA Wei. Interpretation of the Diagnosis of Non-tuberculous Mycobacteria Disease [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 116-119. |
[14] | GUO Qian, SHEN Chen. The progress of non-tuberculous mycobacterium disease in children [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 184-188. |
[15] | JI Xin-fen. Investigation and analysis of a imported family cluster coronavirus disease 2019 case in Pingliang City of Gansu Province [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 58-61. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||